Auxilium Biotechnologies
HardwareSan Diego, California, USAFounded 2019
Auxilium Biotechnologies develops 3D bioprinting technology for producing implantable medical devices, with a focus on peripheral nerve repair.
- CEO / Founder
- Jacob Koffler, PhD, MBA
- Team Size
- 11-50 employees
- Stage
- Operational with successful deployment on the ISS
- Total Funding
- $3.25M
- Latest Round
- Raised $3,249,988 from 18 investors on 2020-01-21
- Key Investors
- ["Undisclosed"]
Technology & Products
Key Products
["AMP-1 3D bioprinter","Gen 1.0 NeuroSpan Bridge"]
Technological Advantage
Ability to fabricate complex biomedical structures in space, which is not possible with conventional Earth-based 3D bioprinting methods.
Market & Competition
Target Customers
Medical institutions and patients requiring nerve repair treatments
Industry Verticals
["Biomedical","Neurological"]
Competitors
["Organovo Holdings","Aspect Biosystems","Regeneron Pharmaceuticals"]